«HER2 - positive, ER - positive tumors have molecular features distinct from those of HER2 - positive, ER - negative cancers, suggesting that the two types of tumors should be treated with
differently tailored approaches,» wrote study authors led by Luca Gianni, MD, of San Raffaele Scientific Institute in Milan.